Global Juvenile Macular Degeneration Treatment Market Projected to Reach $1.87 Billion by 2029 at a CAGR of 7.8%
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Juvenile Macular Degeneration Treatment Market Size From 2025 to 2034?
The market for treating juvenile macular degeneration has seen substantial expansion in the past few years. A surge from $1.28 billion in 2024 to $1.39 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%, is anticipated. The previous period’s expansion can be linked to a rise in genetically linked eye maladies, augmenting investments in eye-related research, amplified attention towards children’s eye health, escalating cases of visual defects among youngsters, and the increasingly prevalent use of artificial intelligence in ocular diagnostic procedures.
The market size for juvenile macular degeneration treatments is projected to experience a robust growth in the upcoming years. The market is predicted to expand to$1.87 billion in 2029, with a compound annual growth rate (CAGR) of 7.8%. This foreseen surge within the forecast period is due to factors such as an increase in the aged populace, a proliferation of startup companies focused on ophthalmic biotechnology, an intensified concentration on targeted drug delivery systems, a rising count of clinical trials, and enhanced investments in gene therapy. Key trends noticed within the forecast period encompass advancements in genetic testing, progress in gene therapies, research in stem cells, regulatory backing for cutting-edge therapies, and individualized medicine strategies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23433&type=smp
What are the Fundamental Drivers and Innovations Shaping the Juvenile Macular Degeneration Treatment Market?
The growth of the juvenile macular degeneration treatment market is projected to be driven by the rising incidence of retinal disorders. These disorders are conditions that impact the retina – the area of the eye sensitive to light – and can cause vision problems or even blindness. The prevalence of retinal disorders has been increasing due to a surge in diabetes cases, which often lead to complications like diabetic retinopathy that deteriorate the retina over time. Juvenile macular degeneration treatments play a key role in managing retinal disorders, as they help maintain vision by intervening early, especially in young patients. For example, in November 2024, Retina Australia, a non-profit organization based in Australia, reported that an estimated 1 in 1,380 people, or nearly 19,000 individuals in Australia, are living with an inherited retinal disease (IRD). Additionally, the National Eye Institute, a health institution based in the US, predicts that the number of Americans suffering from advanced age-related macular degeneration (AMD) is projected to rise from the present figure of 2.1 million to 3.7 million by 2030. As such, the escalating incidence of retinal disorders is fueling the expansion of the juvenile macular degeneration treatment market.
How Is the Juvenile Macular Degeneration Treatment Market Segmented?
The juvenile macular degeneration treatmentmarket covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration; Dry Age-Related Macular Degeneration
2) By Treatment: Devices; Drugs; Surgery
3) By Application: Vision Preservation; Disease Management; Symptom Relief; Preventive Care; Clinical Trials
4) By Sales Channel: Hospitals; Ambulatory Surgical Centres; Other Sales Channel
Subsegments:
1) By Wet Age-Related Macular Degeneration: Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapy; Photodynamic Therapy (PDT); Laser Therapy
2) By Dry Age-Related Macular Degeneration: Nutritional Supplements; Gene Therapy; Stem Cell Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23433&type=smp
Which Regions Are Driving the Next Phase of the Juvenile Macular Degeneration Treatment Market Growth?
North America was the largest region in the juvenile macular degeneration treatment market in 2024. The regions covered in the juvenile macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Juvenile Macular Degeneration Treatment Market?
Leading businesses in the juvenile macular degeneration treatment market are concentrating on creating innovative solutions, for example, dual adeno-associated viral (AAV) vectors aimed at enhancing the delivery of gene therapy and bolstering the treatment effectiveness for patients suffering from juvenile macular degeneration. The strategy of using dual AAV vectors is a method in gene therapy that involves the use of two AAV vectors to administer large therapeutic genes, going beyond the packaging capacity of a single AAV. Take for example, in March 2025, the biotechnology company based in Spain, SpliceBio, declared the initial patient dosing in its Phase 1/2 ASTRA study for SB-007, a dual AAV vector gene therapy anticipated to restore full-length ABCA4 protein expression. The goal of this therapy is to offer a promising treatment for juvenile macular degeneration (also known as stargardt disease), a genetically acquired retinal disease currently without accepted treatments by considering all patients, irrespective of their mutations. This achievement signifies an important advancement towards the creation of effective gene therapies for rare eye diseases associated with the retina.
View the full report here:
How Is the Juvenile Macular Degeneration Treatment Market Defined and What Are Its Core Parameters?
Juvenile macular degeneration (stargardt disease) treatment refers to a range of strategies aimed at managing vision loss and improving quality of life for individuals affected by this genetic eye disorder. It is caused by genetic mutations that damage the macula, the central part of the retina, leading to gradual vision loss and difficulty with tasks like reading and recognizing faces.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23433
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
